Scientific Program
Please note: All presentations indicated with * are available for on demand viewing only until Monday, November 21, 2022. Those underlined were live-steamed only and not avaiable in this on demand program.
| DAY 1 – Friday, November 11, 2022 All timing in CET |
|
| 11:00-11:10 | Welcome address: Naveen Pemmaraju, USA, Claire Harrison, UK & Ruben Mesa, USA Congress Co-Chairs |
| 11:10-13:05 | Session 1: Polycythemia Vera in 2022 and beyond Moderator: Laura Michaelis, USA |
| 11:10-11:15 | Welcome from the moderator |
| 11:15-11:35 | Debate: Standard of care in PV |
| 11:15-11:25 | IFN: Richard Silver, USA |
| 11:25-11:35 | HU, other: Brady Stein, USA |
| 11:35-11:55 | Treatment updates: Ropeginterferon in 2022: Jean-Jacques Kiladjian, France |
| 11:55-12:15 | Clinical trial update: PTG-300/Rusfertide: from bench to bedside Hepcidin Mimetics in PV: Ronald Hoffman, USA |
| 12:15-12:35 | Debate: Future directions in PV |
| 12:15-12:25 | Molecular risk stratification, better understanding of MPN stem cell biology will guide future therapy approaches: Jerry Spivak, USA |
| 12:25-12:35 | Clinical factors, sustained HCT reduction, symptom burden, thrombosis/ bleeding risk to guide future therapy options in PV: Laura Michaelis, USA |
| 12:35-13:05 | Panel discussion |
| 13:05-14:50 | Session 2: Essential thrombocytosis: state-of-the-art Moderator: Claire Harrison, UK |
| 13:05-13:10 | Welcome from the moderator |
| 13:10-13:30 | Debate: Low-dose ASA in ET: standard of care in ET |
| 13:10-13:20 | Pro: Lucia Masarova, USA |
| 13:20-13:30 | Con: Alessandro Vannucchi, Italy |
| 13:30-13:50 | Higher risk ET: state-of-the-art management in 2022: Claire Harrison, UK |
| 13:50-14:10 | CALR mutations: from 2013 to present – a review: Ian Hitchcock, UK |
| 14:10-14:30 | CALR and ET: Role of immunotherapy as future directions/novel approaches: Ann Mullally, USA |
| 14:30-14:50 | Panel discussion |
| 14:50-15:00 | Program pause |
| 15:00-17:30 | Session 3: Myelofibrosis: current and novel approaches in a rapidly developing field Moderator: Naveen Pemmaraju, USA |
| 15:00-15:05 | Welcome from the moderator |
| 15:05-15:25 | Early/lower risk MF: treatment options and approach: Ruben Mesa, USA |
| 15:25-15:45 | Int/higher risk MF: current treatment options in 2022: Srdan Verstovsek, USA |
| 15:45-16:05 | Anemia in MF: emerging area for novel approaches: Naveen Pemmaraju, USA |
| 16:05-16:25 | Debate: Novel therapies in MF as single agents beyond JAKi |
| 16:05-16:15 | Importance of overall survival as endpoints, novel agents: John Mascarenhas, USA |
| 16:15-16:25 | Importance of spleen volume/Sxs burden, reduction of novel agents: Prithviraj Bose, USA |
| 16:25-16:45 | Debate: Novel therapies in combinations in MF: an emerging new era |
| 16:25-16:35 | With JAKi – important steps forward in patient management: Naveen Pemmaraju, USA |
| 16:35-16:45 | In MF: Beware of toxicities, complications to monitor for as we enter combination era: Aaron Gerds, USA |
| 16:45-17:05 | Debate: SCT in MF: European and American perspectives: |
| 16:45-16:55 | US: Tania Jain, USA |
| 16:55-17:05 | * European: Ibrahim Yakoub-Agha, France |
| 17:05-17:30 | Panel discussion |
| 17:30-19:15 | Session 4: AYA MPNs: pregnancy, thromboses, unique aspects Moderator: Gabriela Hobbs, USA |
| 17:30-17:35 | Welcome from the moderator |
| 17:35-17:55 | * Pediatric and MPN AYAs: an overview and cohort experience: Nicole Kucine, USA |
| 17:55-18:15 | Pregnancy, fertility and hormone therapy: state-of-the-art considerations: Susan Robinson, UK |
| 18:15-18:35 | Young patients with MPNs: unique considerations in thromboses: Gabriela Hobbs, USA |
| 18:35-18:55 | Pediatric AYA MPN: European perspective: Jean-Jacques Kiladjian, France |
| 18:55-19:15 | Panel discussion |
| DAY 2- Saturday, November 12, 2022 All timing in CET |
|
| 11:00-11:10 | Welcome: Naveen Pemmaraju, USA, Claire Harrison, UK & Ruben Mesa, USA Congress Co-Chairs |
| 11:10-13:00 | Session 5: Rare MPNs – Focus on emerging subtypes Moderator: Deepti Radia, UK |
| 11:10-11:15 | Welcome from the moderator |
| 11:15-11:35 | Updates in the classification of eosinophilic and mast cell disorders: Jason Gotlib, USA |
| 11:35-11:55 | Aggressive SM: emerging therapy options: Deepti Radia, UK |
| 11:55-12:15 | Debate: MDS/MPN overlap syndromes: CMML |
| 11:55-12:05 | US perspective: Mrinal Patnaik, USA |
| 12:05-12:15 | European perspective: Daniel Wiseman, UK |
| 12:15-12:35 | 8p11 Syndrome /MLN eosinophilia: emerging targeted approaches: Andreas Reiter, Germany |
| 12:35-13:00 | Panel discussion |
| 13:00-14:50 | Session 6: CHIP and inflammation in MPNs Moderator: Angela Fleischman, USA |
| 13:00-13:05 | Welcome from the moderator |
| 13:05-13:25 | * CHIP and MPNs – 2022 report: David Steensma, USA |
| 13:25-13:45 | Diet, Inflammation and MPNs: Angela Fleischman, USA |
| 13:45-14:05 | Debate: Future directions: inflammation in MPNs |
| 13:45-13:55 | *Emphasis on CHIP, prior conditions, molecular markers leading to MPN: Steffen Koschmieder, Germany |
| 13:55-14:05 | Emphasis on novel, molecular, translational markers in MF: Stephen Oh, USA |
| 14:05-14:25 | MPN mutations start younger than we thought: in-utero observations: Jyoti Nangalia, UK |
| 14:25-14:50 | Panel discussion |
| 14:50-15:00 | Program pause |
| 15:00-16:50 | Session 7: Role of future of pathology and molecular markers in MPNs: current and future directions Moderator: Naveen Pemmaraju, USA |
| 15:00-15:05 | Welcome from the moderator |
| 15:05-15:25 | Debate: Role of next generation sequencing in MPNs: from bench to bedside |
| 15:05-15:15 | Molecular markers heralding time of progression from MPN to AML: checking molecular panel at time of clonal evaluation: Raajit Rampal, USA |
| 15:15-15:25 | Molecular markers at baseline MPN dx: important for initial assessment for all patient for risk stratification: Andrew Kuykendall, USA |
| 15:25-15:45 | Debate: Role of expert hematopathologist in MPNs: virtual second opinions, digital pathology, molecular phenotyping |
| 15:25-15:35 | WHO classification – new updates from a hemapathologist’s perspective: what’s news/ what’s changed: Sanam Loghavi, USA |
| 15:35-15:45 | A day in the life of a hemapathologist working up a case of MF: what is same, what is new? Kamran Mirza, USA |
| 15:45-16:05 | WHO classification in MPNs: an evolving paradigm: Joseph Khoury, USA |
| 16:05-16:25 | AI-based morphological fingerprinting in MPNs: Daniel Royston, UK |
| 16:25-16:50 | Panel discussion |
| 16:50-18:30 | Session 8: What are best practices for MPN care in 2022 across the world? Moderator: Ruben Mesa, USA |
| 16:50-16:55 | Welcome from the moderator |
| 16:55-17:05 | How to build and maintain a rare disease clinical and research program: Naveen Pemmaraju, USA |
| 17:05-17:25 | MPN service infrastructure – running a service line: nursing/research/virtual: Raajit Rampal, USA |
| 17:25-17:45 | MPN center needs and future directions: a model system in the UK as case study: Claire Harrison, UK |
| 17:45-18:05 | MPN program clinical/translational development strategies future directions: Ruben Mesa, USA |
| 18:05-18:30 | Panel discussion |
| 18:30-18:45 | Closing remarks: Naveen Pemmaraju, USA, Claire Harrison, UK & Ruben Mesa, USA Congress Co-Chairs |